LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Начало・Списък с акции・Compugen Ltd

Compugen Ltd

Затворен

1.95 -2.5

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.95

Максимум

2.03

Ключови измерители
By Trading Economics
Приходи	-65M -7.7M
Продажби	-65M 2.2M
P/E Средно за сектора	5.368 49.052
EPS	-0.08
Марж на печалбата	-352.436
Служители	75
EBITDA	-64M -7.7M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+155.1% upside

Дивиденти
By Acuity
Следващи печалби	5.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-77M 193M
Предишно отваряне	4.45
Предишно затваряне	1.95

Compugen Ltd Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.06.2026 г., 23:36 ч. UTC

Correction to Oracle Reports Higher 4Q Profit Article

10.06.2026 г., 23:19 ч. UTC

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

10.06.2026 г., 23:09 ч. UTC

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

10.06.2026 г., 23:04 ч. UTC

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

10.06.2026 г., 20:44 ч. UTC

Caterpillar Raises Quarterly Dividend 8%

10.06.2026 г., 23:49 ч. UTC

Elliott: Northern Star Should Take No Options Off The Table

10.06.2026 г., 23:48 ч. UTC

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

10.06.2026 г., 23:48 ч. UTC

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

10.06.2026 г., 23:47 ч. UTC

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

10.06.2026 г., 23:47 ч. UTC

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

10.06.2026 г., 23:46 ч. UTC

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

10.06.2026 г., 23:38 ч. UTC

Global Equities Roundup: Market Talk

10.06.2026 г., 23:38 ч. UTC

Global Forex and Fixed Income Roundup: Market Talk

10.06.2026 г., 23:38 ч. UTC

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

10.06.2026 г., 23:32 ч. UTC

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

10.06.2026 г., 23:20 ч. UTC

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

10.06.2026 г., 22:05 ч. UTC

Correction to Bank of Canada Stays on Hold Market Talk

10.06.2026 г., 21:57 ч. UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10.06.2026 г., 21:52 ч. UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10.06.2026 г., 21:35 ч. UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10.06.2026 г., 21:22 ч. UTC

Oracle Stock Slides on Increased Capital Spending -- WSJ

10.06.2026 г., 20:50 ч. UTC

Tech, Media & Telecom Roundup: Market Talk

10.06.2026 г., 20:50 ч. UTC

Financial Services Roundup: Market Talk

10.06.2026 г., 20:50 ч. UTC

Basic Materials Roundup: Market Talk

10.06.2026 г., 20:50 ч. UTC

Health Care Roundup: Market Talk

10.06.2026 г., 20:39 ч. UTC

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

10.06.2026 г., 20:34 ч. UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10.06.2026 г., 20:33 ч. UTC

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

10.06.2026 г., 20:33 ч. UTC

Global Equities Roundup: Market Talk

10.06.2026 г., 20:33 ч. UTC

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Compugen Ltd Прогноза

Ценова цел

By TipRanks

155.1% нагоре

12-месечна прогноза

Среден 5 USD 155.1%

Висок 6 USD

Нисък 4 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Compugen Ltd през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

3 ratings

Купи

Задържане

Продай

Според 3 анализатори, дали борсови рейтинги на Compugen Ltd през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.